BR112016029437A2 - métodos para tratamento e prevenção de doenças de instabilidade vascular - Google Patents

métodos para tratamento e prevenção de doenças de instabilidade vascular

Info

Publication number
BR112016029437A2
BR112016029437A2 BR112016029437A BR112016029437A BR112016029437A2 BR 112016029437 A2 BR112016029437 A2 BR 112016029437A2 BR 112016029437 A BR112016029437 A BR 112016029437A BR 112016029437 A BR112016029437 A BR 112016029437A BR 112016029437 A2 BR112016029437 A2 BR 112016029437A2
Authority
BR
Brazil
Prior art keywords
methods
disclosed
ccm
patient
cavernous malformation
Prior art date
Application number
BR112016029437A
Other languages
English (en)
Other versions
BR112016029437B1 (pt
Inventor
C Gibson Christopher
Y Li Dean
Original Assignee
The Univ Of Utah Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Univ Of Utah Research Foundation filed Critical The Univ Of Utah Research Foundation
Publication of BR112016029437A2 publication Critical patent/BR112016029437A2/pt
Publication of BR112016029437B1 publication Critical patent/BR112016029437B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0033—Features or image-related aspects of imaging apparatus classified in A61B5/00, e.g. for MRI, optical tomography or impedance tomography apparatus; arrangements of imaging apparatus in a room
    • A61B5/004—Features or image-related aspects of imaging apparatus classified in A61B5/00, e.g. for MRI, optical tomography or impedance tomography apparatus; arrangements of imaging apparatus in a room adapted for image acquisition of a particular organ or body part
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves 
    • A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves  involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Surgery (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

resumo ?métodos para tratamento e prevenção de doenças de instabilidade vascular? métodos são divulgados para tratar e prevenir doenças de instabilidade vascular, tais como malformação cavernosa cerebral, por meio da administração de tempol, colecalciferol, derivados dos mesmos, sais farmaceuticamente aceitáveis dos mesmos ou combinações dos mesmos. métodos são divulgados para reduzir o número de lesões por malformação cavernosa cerebral (ccm) em um paciente que apresenta, ou em risco de desenvolver, pelo menos uma lesão por ccm. métodos são divulgados para reduzir a taxa de crescimento do número de lesões por malformação cavernosa cerebral (ccm) em um paciente que apresenta, ou em risco de desenvolver, pelo menos uma lesão por ccm. métodos são divulgados para prevenir ou tratar um sinal ou sintoma de malformação cavernosa cerebral (ccm) em um paciente com pelo menos uma lesão por ccm. métodos são divulgados para reduzir inflamação cerebrovascular e/ou reduzir permeabilidade cerebrovascular em um paciente que apresenta, ou em risco de desenvolver, uma lesão por malformação cavernosa cerebral (ccm). métodos são divulgados para melhorar a saúde cerebro-vascular em um paciente que apresenta, ou em risco de desenvolver, uma lesão por malformação cavernosa cerebral (ccm).
BR112016029437-8A 2014-06-19 2015-06-16 Usos terapêuticos de uma composição compreendendo tempol, colecalciferol ou um sal farmaceuticamente aceitável dos mesmos associados à malformação cavernosa cerebral BR112016029437B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462014540P 2014-06-19 2014-06-19
US62/014,540 2014-06-19
US14/728,800 US9314457B2 (en) 2014-06-19 2015-06-02 Methods of treating and preventing vascular instability diseases
US14/728,800 2015-06-02
PCT/US2015/036062 WO2015195685A1 (en) 2014-06-19 2015-06-16 Methods of treating and preventing vascular instability diseases

Publications (2)

Publication Number Publication Date
BR112016029437A2 true BR112016029437A2 (pt) 2017-08-22
BR112016029437B1 BR112016029437B1 (pt) 2022-11-29

Family

ID=54868659

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016029437-8A BR112016029437B1 (pt) 2014-06-19 2015-06-16 Usos terapêuticos de uma composição compreendendo tempol, colecalciferol ou um sal farmaceuticamente aceitável dos mesmos associados à malformação cavernosa cerebral

Country Status (14)

Country Link
US (2) US9314457B2 (pt)
EP (1) EP3157532B1 (pt)
JP (1) JP6621424B2 (pt)
KR (1) KR102419504B1 (pt)
CN (1) CN106659727B (pt)
AU (1) AU2015277341B2 (pt)
BR (1) BR112016029437B1 (pt)
CA (1) CA2949545C (pt)
DK (1) DK3157532T3 (pt)
ES (1) ES2879331T3 (pt)
IL (1) IL249599B (pt)
MX (1) MX2016015695A (pt)
RU (1) RU2712170C2 (pt)
WO (1) WO2015195685A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9314457B2 (en) * 2014-06-19 2016-04-19 The University Of Utah Research Foundation Methods of treating and preventing vascular instability diseases
WO2017180841A1 (en) * 2016-04-13 2017-10-19 The Regents Of The University Of California Treatment of cerebral cavernous malformations
CN106226531B (zh) * 2016-07-25 2018-05-22 广州道瑞医药科技有限公司 Angpt2在筛选或制备用于诊断或治疗血管瘤的药物中的应用
US20210128527A1 (en) * 2017-12-08 2021-05-06 Graham Timmins Compositions and methods for treating hemorrhagic stroke
US20220378765A1 (en) * 2021-05-25 2022-12-01 Louis Habash Adjusting expression level of a gene encoding a sirtuin protein by treating a human subject with a nitroxide

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096759A (en) 1997-09-19 2000-08-01 Georgetown University Method for treating essential hypertension
US6331532B1 (en) 1998-11-25 2001-12-18 University Of Otago Mitochondrially targeted antioxidants
JP4590523B2 (ja) 1997-11-25 2010-12-01 アンティポディーン ファーマシューティカルズ インコーポレイテッド ミトコンドリアを標的とする抗酸化剤
WO2002026231A1 (en) 2000-09-26 2002-04-04 Georgetown University Use of nitroxides for the treatment of vascular disorders in a diabetic mammal
NZ513547A (en) 2001-08-13 2002-09-27 Antipodean Biotechnology Ltd Synthesis of triphenylphosphonium quinols (e.g. mitoquinol) and/or quinones (e.g. mitoquinone)
WO2003096991A2 (en) 2002-05-17 2003-11-27 Othera Pharmaceuticals, Inc. Amelioration of the development of cataracts and other opthalmic diseases
AU2005208821B8 (en) 2003-02-04 2010-10-14 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
AU2004233862A1 (en) * 2003-04-25 2004-11-11 Mitos Pharmaceuticals, Inc. Prophylactic pretreatment with antioxidants
RU2487880C2 (ru) 2003-08-22 2013-07-20 Антиподин Фармасьютикалз Инк. Направленно вводимые в митохондрии производные убихинона в качестве антиоксидантов для снижения окислительного стресса, фармацевтическая композиция, способ получения, способ лечения
US7585846B2 (en) 2003-11-25 2009-09-08 University Of Rochester Compounds for delivering amino acids or peptides with antioxidant activity into mitochondria and use thereof
RU2264241C2 (ru) * 2004-02-05 2005-11-20 Российский научно-исследовательский нейрохирургический институт им. проф. А.Л. Поленова Способ лечения поражений зрительного анализатора
US20070167419A1 (en) * 2005-03-02 2007-07-19 The Regents Of The University Of California Treatment for embolic stroke
AU2006236590A1 (en) 2005-04-14 2006-10-26 Cary Pharmaceuticals Combination formulation
US7691896B2 (en) 2005-08-10 2010-04-06 President And Fellows Of Harvard College Analogs of salinosporamide A
US7838023B2 (en) 2005-11-16 2010-11-23 Nitromed, Inc. Furoxan compounds, compositions and methods of use
US7910607B2 (en) * 2006-03-10 2011-03-22 The Trustees Of California State University Nitroxide free radical synergized antineoplastic agents
US20070275944A1 (en) 2006-04-05 2007-11-29 The Board Of Trustees Operating Michigan State University Antioxidants and methods of their use
WO2007149484A2 (en) 2006-06-20 2007-12-27 Dana-Farber Cancer Institute Inhibitors of usp1 deubiquitinating enzyme complex
US7923037B2 (en) 2006-10-05 2011-04-12 Ikaria, Inc. Liquid chalcogenide compositions and methods of manufacturing and using the same
WO2008101195A2 (en) 2007-02-16 2008-08-21 Othera Holding, Inc. Drug resistance reversal in neoplastic disease
US8466130B2 (en) * 2009-09-04 2013-06-18 Colby Pharmaceutical Company Mitochondria targeted cationic anti-oxidant compounds for prevention, therapy or treatment of hyper-proliferative disease, neoplasias and cancers
MX356129B (es) 2008-01-22 2018-05-16 Araim Pharmaceuticals Inc Peptidos y analogos de peptidos protectores de los tejidos para evitar y tratar padecimientos y desordenes asociados con daño de los tejidos.
US20100081689A1 (en) 2008-09-26 2010-04-01 Georgetown University Methods and Compositions for the Treatment of Iron Toxicity
US20110130421A1 (en) 2009-10-29 2011-06-02 Georgetown University Methods and Compositions for the Treatment of Chronic Renal Hypertension
WO2011066537A1 (en) 2009-11-30 2011-06-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nitroxide therapy for the treatment of von hippel - lindau disease (vhl) and renal clear cell carcinoma (rcc)
RU2476249C2 (ru) * 2011-06-02 2013-02-27 Федеральное государственное учреждение "Центральный научно-исследовательский институт стоматологии и челюстно-лицевой хирургии" Министерства здравоохранения и социального развития Российской Федерации Способ лечения сосудистых мальформаций
KR20130016127A (ko) 2011-08-04 2013-02-14 의료법인 성광의료재단 외상성 뇌손상의 치료
US9314457B2 (en) * 2014-06-19 2016-04-19 The University Of Utah Research Foundation Methods of treating and preventing vascular instability diseases

Also Published As

Publication number Publication date
KR20170021249A (ko) 2017-02-27
DK3157532T3 (da) 2021-06-28
EP3157532A1 (en) 2017-04-26
AU2015277341A1 (en) 2016-12-01
US9937162B2 (en) 2018-04-10
JP6621424B2 (ja) 2019-12-18
RU2016145265A (ru) 2018-07-19
CN106659727A (zh) 2017-05-10
US20150366848A1 (en) 2015-12-24
IL249599B (en) 2021-06-30
IL249599A0 (en) 2017-02-28
KR102419504B1 (ko) 2022-07-12
MX2016015695A (es) 2017-05-30
RU2016145265A3 (pt) 2019-02-04
ES2879331T3 (es) 2021-11-22
CN106659727B (zh) 2020-06-16
JP2017518340A (ja) 2017-07-06
EP3157532B1 (en) 2021-03-24
CA2949545C (en) 2022-07-19
BR112016029437B1 (pt) 2022-11-29
RU2712170C2 (ru) 2020-01-24
AU2015277341B2 (en) 2020-06-25
EP3157532A4 (en) 2017-12-20
US20160220546A1 (en) 2016-08-04
WO2015195685A1 (en) 2015-12-23
CA2949545A1 (en) 2015-12-23
US9314457B2 (en) 2016-04-19

Similar Documents

Publication Publication Date Title
PH12020500352A1 (en) Therapeutic uses of empagliflozin
BR112018002046A2 (pt) métodos de tratamento da síndrome de lennox-gastaut usando fenfluramina
MX2021004821A (es) Uso de antagonistas contra muerte programada 1 (pd-1) y ligando de muerte programada 1 (pd-l1) en combinacion con radioterapia.
TW201613887A (en) Antiproliferative compounds and methods of use thereof
BR112016029437A2 (pt) métodos para tratamento e prevenção de doenças de instabilidade vascular
BR112015027282A2 (pt) fenfluramina para uso no tratamento de síndrome de dravet
MY189333A (en) Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii
BR112017007144A2 (pt) ácido valproico ou um sal farmaceuticamente aceitável do mesmo, composto, composição farmacêutica, e, composto ou composição para uso, uso, método ou composição.
MX2020013740A (es) Uso de empagliflozina para el tratamiento de trastornos metabolicos, la prevencion, y para la reduccion del riesgo de sufrir o para retrasar la ocurrencia de un episodio cardiovascular.
BR112019008384A2 (pt) composição farmacêutica, processos para tratamento e seus usos
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
MX2017015012A (es) Formulaciones tópicas y orales que comprenden taurina y magnesio para la prevención y el tratamiento del acné.
BR112017015576A2 (pt) método para o tratamento de câncer, artigo, método para monitorizar, método para a otimização da eficácia terapêutica, método para a identificação de um biomarcador, utilização, combinação terapêutica, combinação para a utilização e produto
EA201790726A1 (ru) Фармацевтическая композиция для лечения язвенного колита
BR112017013674A2 (pt) métodos e composições para tratamento de doenças cerebrais.
MX2016011881A (es) Medicamento de peptido en polvo seco.
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
TW201613639A (en) Methods for treating cardiovascular diseases
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
BR112017007364A2 (pt) composição farmacêutica para o uso no tratamento ou prevenção de deficiências de vitaminas e minerais em pacientes que foram submetidos à cirurgia de bypass gástrico
NZ754706A (en) Use of lactic acid bacteria to treat or prevent gestational diabetes mellitus
IN2014DN09240A (pt)
BR112017002449A2 (pt) tratamento de sintomas associados com terapia de privação androgênica
EA202193276A1 (ru) Способы лечения холангиокарциномы
PH12016502107A1 (en) Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/06/2015, OBSERVADAS AS CONDICOES LEGAIS